The Rabies
Vaccine Market in Asia Pacific is expected to witness new entrants and is a
major competitive market due to the burden of rabies. According to data
published by the World Health Organization (WHO) in 2017, India accounts for
59.9% of deaths due to rabies in Asia, and 35% of deaths globally. Major
players operating in the region are Yisheng Biopharma, Serum Institute of
India, Zuventus, and Bharat Biotech Ltd. Moreover companies such as Yisheng
Laboratories and CPL Laboratories (India) have vaccine candidates in clinical
trials.
Rabies is a viral zoonotic
disease caused through a dog’s bite which leads to progressive and fatal
inflammation of the brain and spinal cord. There are two type of rabies;
furious rabies and paralytic rabies. Symptoms accompanied with furious rabies
are hyperactivity and hallucination. Paralytic rabies can cause coma and
paralysis. Rabies seems fatal disease but it can be controlled through vaccines
and medicines which have long been available to prevent death by rabies.
According World Health Organization (WHO), globally rabies cause fatalities
nearly 10,000 people yearly and almost 99% cases are due to dog bites. Symptoms
caused by rabies are wound, fever with pain near the wound, tingling, pricking
at wound site, and if not treated properly it can lead to cardiac or
respiratory arrest. According to World Health Organization (WHO), in 2017,
rabies caused 59,000 deaths annually in 150 countries with 95% cases in rural
districts.
Global Rabies Vaccines Market-
Drivers
Key players are focused on
research and development strategies which are expected to drive the global
rabies vaccine market growth during the forecast period. For instance, in 2017,
CPL Laboratories (India), a joint venture biotechnology company established in
2009 by Novavax Inc., USA and Cadila Pharmaceuticals Limited, stated that Nano-
particle vaccine of baculvirous-derived glycoprotein, a four dose regime
vaccine is in phase-3 human trial, and is expected to be approved by 2021.
In U.S., rabies in early 1960 to
2000 was negligible, and witnessed a sudden rise resulting in 100 cases
annually. Although the fatalities were
rare, lack of awareness towards rabies is proving to be a risk. From 1960 to
2018, 127 cases of rabies were reported in U.S. from dog bites and bat bites.
Whereas in Asia, rabies is a major burden, accounting for almost 35,000 deaths,
fatalities caused by rabies in India are 55%.
In Africa, an estimated 21,476 human deaths occur due to dog bite rabies,
Africa spends less on the post exposure prophylaxis treatment of rabies and
have highest mortality rate due to rabies. Central Asia and Middle East Asia
have an estimated 1875 and 229 fatalities yearly. These factors are is expected
to drive the global rabies vaccines market growth during the forecast period.
Global Rabies Vaccines
Market-Impact of COVID-19 Analysis on the Global Rabies Vaccine Market
The impact of COVID-19 on the
global rabies vaccine market has affected every market around the globe in a
negative way. As the world still struggles to recover from the COVID-19
situation it will take a long time for every market to recover its losses.
People have been reluctant to visit the physicians for vaccination due to
social distancing. As per the situation, the impact of COVID-19 has strongly
affected the future market opportunities, revenue growth graph, and the profit
gains of the business for global rabies vaccine market.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/4005
Global Rabies Vaccines Market -
Restraints
Emerging economies in Africa and
Asia are expected to witness a major burden of rabies due to lack of awareness
and costly treatment. Post exposure, prophylaxis is a dose regime for dog
mediated rabies. According to World Health Organization (WHO), in 2017, the
estimated cost of PEP was US $1.5 million, which can make it unaffordable in
mid- or low-income countries and restrain the growth of the global rabies
vaccines market during the forecast period.
Global Rabies Vaccine Market –
Regional Analysis
Regional segmentation of the
global rabies vaccine market includes North America, Latin America, Europe,
Asia Pacific, Middle East, and Africa. North America is projected to dominate
the global rabies vaccines market with the largest share during the forecast
period. The rising investments by governments in the public sector, as well as
programs to eradicate rabies are favouring growth of the market in the region.
For instance, countries in North America in 2008 established the North America
Rabies Management Plan, by assessing and defining the needs, priorities to
control rabies and eventually eliminate it from Canada, Mexico, and the U.S.
According to the European Centre
for Disease Prevention and Control, in 2014 only 3 cases of rabies were
reported in Europe, whereas Europe being the highest vaccine manufacturer for
rabies. Key market players in Europe are GlaxoSmithKline, Sanofi–Pasteur and
Novartis AG.
Furthermore, the market in Asia
Pacific is expected to witness significant growth owing to active involvement
by manufacturers in Asia Pacific countries such as China, Japan and India
regarding development of innovative rabies vaccine and its substitutes. In
February 2018, BioNote, Inc., a South Korean veterinary diagnostic company
operating in rabies diagnostics, announced the launch of a new
immune-fluorescent device, Vcheck, which can measure diagnostic result values
with the help of fluorescent materials which help in detecting the zoonotic
disease in animals.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/rabies-vaccine-market-4005
Global Rabies Vaccine Market-
Competitive Landscape
Key players operating in global
rabies vaccine market are Sanofi S.A., Novartis International AG, Serum
Institute of India Pvt. Ltd, Indian Immunologicals Limited, Bharat Biotech Ltd,
Zuventus HealthCare Ltd., Cpl Biologicals Private Limited, Yisheng Biopharma
Co., Ltd, GlaxoSmithKline plc, Bavarian Nordic A/S, and Chiron Behring Vaccines
Private Limited.
Key Developments-
In 2016, Serum Institute of
India, developed new rabies vaccine, RABIVAS-S, for countries with highest
burden of rabies.
The World Organization for Animal
Health (OIE), a vaccine bank, was established in 2012 with production order for
rabies vaccine of 50,000 doses in 31st December 2016. The OIE recorded 16
million doses of vaccines in 24 countries for pre- and post-exposure
prophylaxis treatment for rabies.
In 2019, Yisheng Biopharma
(Singapore) Pte Ltd stated that development of adjuvant rabies vaccine, PIKA
which is composed of RABIPUR and polyisonic-polycytidcyclic acid, has completed
its phase 2 clinical trial.
In 2019, GlaxoSmithKline divested
its rabies and tick-borne vaccine to Bavarian Nordic, and incurred payment of
$36 million from Bavarian Nordic.
In 2019, Asian subsidiary of
GlaxoSmithKline divested its Chiron Behring Vaccines unit in Gujarat, India to
domestic clinical biotechnology company, Bharat Biotech.
In 2019, Wuhan Institute of
Virology announced positive results of a novel rabies vaccine in pre-clinical
test. The novel vaccine is a live attenuated vaccine; VEEV-RABV-G.
In June 18, 2020 Bavarian Nordic
A/S and Valneva SE announced a partnership for marketing and distribution of
rabies and tick-borne vaccines in selected European countries and Canada.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/4005
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment